Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (774)	11/4/1998 9:35:00 PM
From: Craig Lacy	Read Replies (1) \| Respond to of 3202

I think you guys are making more out of this than is there. Just because INCY has a patent on genomic sequences does not mean that they have a marketable product, the just own information and that information is available to anyone who wants to start sequencing DNA, RNA or protiens. Now, while this may give the company exclusive rights to gene therapy for people with kinase problems (likely a small percentage) other companies can still use the genomic information which is carried in all of us, to develop drugs which solve a medical problem, while not infringing on the company's patents. In other words, my opinion is that while this company has the rights to these sequences and can share this info with perspective buyers, it does not exclude other companies from attaining the information for themselves and developing products based on that information without having to pay royalties. PS I am a shareholder.